Chemoinformaics analysis of N-NONACOSAN-4-OL-18-ONE
| Molecular Weight | 438.781 | nRot | 26 |
| Heavy Atom Molecular Weight | 380.317 | nRig | 1 |
| Exact Molecular Weight | 438.444 | nRing | 0 |
| Solubility: LogS | -6.641 | nHRing | 0 |
| Solubility: LogP | 10.014 | No. of Aliphatic Rings | 0 |
| Acid Count | 0 | No. of Aromatic Rings | 0 |
| Base Count | 0 | No. of Aliphatic Carbocycles Rings | 0 |
| Atoms Count | 89 | No. of Aliphatic Hetero Cycles | 0 |
| No. of Heavy Atom | 31 | No. of Aromatic Carbocycles | 0 |
| nHetero | 2 | No. of Aromatic Hetero Cycles | 0 |
| nBridge Head | 0 | No. Saturated Carbocycles | 0 |
| No. of Hydrogen atom | 58 | No. of Saturated Hetero Cycles | 0 |
| No. of Carbon atom | 29 | No. of Saturated Rings | 0 |
| No. of Nitrogen atom | 0 | No. of Arom Atom | 0 |
| No. of Oxygen atom | 2 | No. of Arom Bond | 0 |
| nHA | 2 | APOL | 88.708 |
| nHD | 1 | BPOL | 59.054 |
| QED | 0.136 |
| Synth | 2.608 |
| Natural Product Likeliness | 0.703 |
| NR-PPAR-gamma | 0.9 |
| Lipinski | Accepted |
| Pfizer | Rejected |
| GSK | Rejected |
| Golden Triangle | Rejected |
| Pgp-inh | 0 |
| Pgp-sub | 0.142 |
| HIA | 0.005 |
| CACO-2 | -5.12 |
| MDCK | 0.00000708 |
| BBB | 0.004 |
| PPB | 0.975093 |
| VDSS | 1.403 |
| FU | 0.00937317 |
| CYP1A2-inh | 0.059 |
| CYP1A2-sub | 0.159 |
| CYP2c19-inh | 0.099 |
| CYP2c19-sub | 0.048 |
| CYP2c9-inh | 0.044 |
| CYP2c9-sub | 0.971 |
| CYP2d6-inh | 0.083 |
| CYP2d6-sub | 0.056 |
| CYP3a4-inh | 0.196 |
| CYP3a4-sub | 0.016 |
| CL | 5.991 |
| T12 | 0.161 |
| hERG | 0.406 |
| Ames | 0.004 |
| ROA | 0.004 |
| SkinSen | 0.956 |
| Carcinogencity | 0.018 |
| EI | 0.907 |
| Respiratory | 0.871 |
| NR-Aromatase | 0.11 |
| Antiviral | No |
| Prediction | 0.658847 |